(1998; 18 pages)
Venlafaxine - review of adverse reactions
Australia. Since marketing in mid-1995 to December 1997, the Adverse Drug Reactions Advisory Committee has received 190 reports of suspected adverse reactions in association with venlafaxine, a new antidepressant that inhibits the neuronal reuptake of both serotonin and noradrenaline.
Most of these (145) implicated venlafaxine as the only suspected drug. Based on these cases, venlafaxine appears to have a greater association than the selective serotonin reuptake inhibitors (SSRIs) with nausea/vomiting/anorexia (54 reports), headache (25), increased sweating (20), syncope (10) and hypertension (9). It may be that these differences, especially syncope and hypertension, are related to venlafaxine's effect on noradrenergic transmission.
Reference: Australian Adverse Drug Reactions Bulletin 17(1): 2 (1998).